mTORC1 shutdown unleashes TFEB to drive triple-negative breast cancer invasion 

    Michalis Gounis et al.

    Dev Cell. 2025 Apr 7;60(7):979-981. doi: 10.1016/j.devcel.2025.03.006.

    Published on April 8, 2025

     

    ABSTRACT

    The PI3K/AKT/mTOR pathway is considered a key therapeutic target in triple-negative breast cancer (TNBC). In this issue of Developmental Cell, Remy et al. challenge this idea by demonstrating that mTORC1 inhibition activates TFEB, promoting MT1-MMP exocytosis, ECM degradation, and increased cell invasion, especially when combined with chemotherapy.

    PMID:40199239 | DOI:10.1016/j.devcel.2025.03.006

     Read More

    Back to Publications
    Recent Publication
    Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease 
    Valeriia Dotsenko et al.BMC Med. 2026 Apr 24. doi: 10.1186/s12916-026-04892-y. Online ahead of print.
    Recent Publication
    Pre- and postnatal maternal psychological distress and the metabolomic profile of human milk 
    Niamh Ryan et al.J Nutr. 2026 Apr 16:101531. doi: 10.1016/j.tjnut.2026.101531. Online ahead of print.
    Recent Publication
    The role of human milk oligosaccharides in shaping and restoring infant gut microbiota: Population-based cohort study 
    Minka Ovaska et al.Am J Clin Nutr. 2026 Apr 16:101318. doi: 10.1016/j.ajcnut.2026.101318. Online ahead of print.
    Recent Publication
    Functional Interplay between Heat Shock Protein 90 (HSP90) and Heat Shock Factors (HSFs) 
    Abir Chakraborty et al.Cell Stress Chaperones. 2026 Apr 9:100177. doi: 10.1016/j.cstres.2026.100177. Online ahead of print.
    Recent Publication
    Testosterone Exposure During Fetal Masculinization Programming Window Determines the Kidney Size in Adult Mice 
    Arttu Junnila et al.FASEB J. 2026 Apr 15;40(7):e71724. doi: 10.1096/fj.202500761RR.